The S&P 500 Index
(^GSPC) endured its steepest slide of the year after GDP unexpectedly contracted in the final quarter of 2012, even if the data was revealed too late to harm President Obama at the polls. (This time Jack Welch didn’t say the delay was the work of those “Chicago guys
” but, with his alma mater General Electric
(GE) ending off 1.20% in posting the Dow’s
(^DJI) poorest performance, his mind may have been elsewhere.)
Research In Motion
(RIMM), which will change its symbol to BBRY, tumbled 12.01% yesterday, and Banco Santander
(SAN), which recently had rather greater justification for changing its symbol from STD
, is tumbling 3.35% in today’s London trading after announcing iffy earnings. RIM’s CEO, proud Teuton Thorsten Heins, would have been driven to drink with its performance, even as his homeland the epicenter of Oktoberfest sees an astonishing decline in ale consumption
On this side of the Atlantic, beer behemoth Anheuser-Busch
(BUD) added on another 0.97% to hit the highest level in its history, and a ratings reduction from analyst David Lipschitz — whose last name you definitely don’t want to try to say while drunk — sent coal company Peabody Energy
(BTU) cratering 6.36%. And an iconic wartime singer who once warbled “Don’t Sit Under the Apple (AAPL) Tree
” sadly passed away. Given the stock’s action September, her advice remains as timeless as ever.
It’s another frenzied session for corporate earnings announcements, with Aetna
(CL), Deutsche Bank
(DB), Eastman Chemical
(EMN), LVMH Moët Hennessy-Louis Vuitton
(MA), Nasdaq OMX
(PHM), Royal Dutch Shell
(RDS-A), United Parcel Service
(VIAB), and Whirlpool
(WHR) all due to report results.
: Janney Capital assigns a new Neutral and $14 price objective on Ironwood Pharmaceuticals
(NASDAQ:IRWD). It begins Buys on Cubist Pharmaceuticals
(NASDAQ:CBST) ($50 target price), DepoMed
(NASDAQ:DEPO) ($12), Forest Laboratories
(NYSE:FRX) ($45), and NPS Pharmaceuticals
(INFI): JPMorgan establishes an Overweight on INFI.
(JOEZ): Roth Capital resumes Buy rated research on the small cap company, assigning it a $2 target.
(SNTS): Leerink launches Outperform rated research on the biotech.
(TRBAA): Shares are begun with a Buy at BWS Financial, whose target is $65.
(See also: Stock Upgrades: Rolls Royce Living Large
and Stock Downgrades: Facebook Defriended All Over Wall Street
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.